Forest Laboratories — Merger or Acquisition (April 2014)
21 slides from Forest Laboratories's merger presentation, Apr 29, 2014
Slide 1: Filed by Forest Laboratories, Inc. Pursuant to Rule 425
Filed by Forest Laboratories, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Forest Laboratories, Inc. Form S-4 File No. 333-194781
Slide 2: Town Hall Meeting
Town Hall Meeting Forest Laboratories Brent Saunders, CEO and President April 29, 2014
Slide 3: Safe Harbor
Safe Harbor Except for the historical information contained herein, this presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because these statements involve a number of risks and uncertainties, actual future results may diff
Slide 4: Safe Harbor - continued
Safe Harbor - continued Neither Forest nor Furiex assumes any obligation to update forward-looking statements contained in this release to reflect new information or future events or developments. Each of Forest and Furiex intends such forward-looking statements to be covered by the Safe Harbor prov
Slide 5: Additional Information and Where to Find It
Additional Information and Where to Find It This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale
Slide 6: Registration statement and proxy information
The registration statement is not yet effective. The definitive Forest/Actavis Proxy and Prospectus will be delivered to security holders of Actavis and Forest. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE FURIEX PROXY, THE FOREST/ACTAVIS PROXY AND PROSPECTUS AND OTHER RELEVANT DOCUMENTS FIL
Slide 7: Participants in the Solicitation
Participants in the Solicitation Forest, Furiex and their directors and certain of their executive officers may be considered participants in the solicitation of proxies from the security holders of Furiex in connection with the proposed transaction between Forest and Furiex. Information about those
Slide 8: Participants in the Solicitation (Actavis and Forest)
Actavis, Forest, their respective directors and certain of their executive officers and employees may be considered participants in the solicitation of proxies in connection with the proposed transaction between Actavis and Forest. Information regarding the persons who may, under the rules of the SE
Slide 9: Agenda
Forest Laboratories, Inc. Agenda • Q4 and FY Accomplishments • Furiex Acquisition • Forest - Actavis Combination • Q&A © 2014 Forest Laboratories Inc. | 8
Slide 10: Maximize the Brands & Launch Performance
Maximize the Brands & Launch Performance Fourth quarter accomplishments Increased sales ~34% to $1 billion; Next 9 products up ~ 70% to $431 million Achieved ~30% NRx conversion to Namenda XR Re-launched Saphris Launched Eziclen in Germany Prepared Linzess DTC Trained & launched GI Specialty Sales F
Slide 11: Deliver on Very Important Near-Term Pipeline
Deliver on Very Important Near-Term Pipeline Fourth quarter accomplishments Submitted Namenda Pediatric Written Request (PWR) Filed Namenda XR + donepezil FDC Filed Bystolic + valsartan FDC Completed positive Phase 2b Data for Cariprazine in depression & Bi Polar depression Completed successful FDA
Slide 12: Reduce Cost Structure Without Impairing Launches or Pipeline Priorities
Reduce Cost Structure Without Impairing Launches or Pipeline Priorities Fourth quarter accomplishments SG&A expenses held flat (excluding Aptalis, Project Rejuvenate expense, Ironwood profit share) R&D expenses decreased 32% (excluding expenses for new acquisitions and milestones) Flattening and Bro
Slide 13: Use Our Balance Sheet to Drive Growth and Create Value
Use Our Balance Sheet to Drive Growth and Create Value Acquired Saphris from Merck Raised $3 billion in debt to fund acquisitions Acquired Aptalis for $2.9 billion Announced proposed $25 billion acquisition by Actavis Announced proposed $1.1 billion acquisition of Furiex © 2014 Forest Laboratories I
Slide 14: Forest Goal is to Build an Exceptional Company
Forest Goal is to Build an Exceptional Company EXECUTION BUSINESS Marketed Drugs development commercial ENGINE AN EXCEPTIONAL COMPANY DRUG NDA development © 2014 Forest Laboratories Inc. 4/29/2014 | 13
Slide 15: Aptalis Integration
Aptalis Integration • Issued $1.8 billion in new debt • Closed deal in 3 weeks • Identified >$125 million in cost synergies • On track to deliver $700 million in annual sales from Aptalis • Integrated U.S., Canada and U.K. Operations • Integrated U.S. Sales Force © 2014 Forest Laboratories Inc. 4/29
Slide 16: Furiex Acquisition Rationale
Furiex Acquisition Rationale • Builds a leading GI company within Forest by adding Eluxadoline – Natural extension following Aptalis acquisition in January – Highly complementary to our anchor GI product Linzess – IBS-D Affects ~ 28 million in US and Europe – High degree of Physician overlap in IBS-
Slide 17: Furiex Transaction Overview
Furiex Transaction Overview • Acquisition of all outstanding shares of Furiex for ~$1.1 B $95 per share • Transaction also includes Contingent Value Right (CVR) of up to $30 per Furiex share (~$360 million in aggregate) $10 per share if eluxadoline is designated schedule IV drug $20 per share if elu
Slide 18: Why Does This Deal with Actavis Make Sense?
Why Does This Deal with Actavis Make Sense? Creates broad & diverse portfolio with multiple blockbuster therapeutic franchises which drive robust organic growth Enables us to spend $1 billion on drug development & research Produces strong cash flow and geographic presence which create opportunity to
Slide 19: What About Me? Successfully Navigating Change
What About Me? Successfully Navigating Change • Attitude is everything – keep an open mind & find ways you can benefit by change • Stay informed on changes communicated within Forest and avoid reacting to rumors or speculation • Don't commiserate • Learn from role models who are highly adaptable • A
Slide 20: What Are Our Priorities in FY 2015?
What Are Our Priorities in FY 2015? 1. Maximize the brand & launch performance 2. Deliver on very important near term pipeline 3. Reduce cost structure without impairing launches or near term pipeline priorities 4. Use our balance sheet to drive growth and create value 5. Complete Actavis deal and b
Slide 21: Town Hall Meeting
Town Hall Meeting Forest Laboratories Brent Saunders, CEO and President April 29, 2014
Forest Laboratories — Merger or Acquisition (April 2014) on 6ix